Skip to main content
Explore URMC

Eric J. Huselton, M.D.

Contact Information

Phone Numbers

Appointment: (585) 275-5823

Fax: (585) 273-1042

URMFGA member of the University of Rochester Medical Faculty Group

groupAn Accountable Health Partner

assignmentAccepting New Patients

Faculty Appointments

Patient Care Settings

Cancer, Hospital Medicine


Dr. Eric Huselton received his medical degree from SUNY Downstate College of Medicine in 2012. He completed an Internal Medicine Residency Training Program and a Hematology/Oncology Fellowship at Washington University in Saint Louis/Bames Jewish Hospital in 2015 and 2018, respectively. Dr. Huselton is certified by the American Board of Internal Medicine.

Dr. Huselton is an Assistant Professor in the Division of Hematology and Oncology at the University of Rochester School of Medicine and Dentistry.

Dr. Huselton's special interests include allogenic hematopoietic cell transplant, haploidentical hematopoietic cell transplant, AML, MDS and hematologic malignancies. He aims to provide the best care by incorporating new treatments based on the most recent data, including clinical trials, targeted therapies, immunotherapy and cellular therapies. Dr. Huselton's hobbies include sailing, hiking and cooking.



MD | SUNY Downstate Medical Center College of Nursing

Post-doctoral Training & Residency

07/01/2015 - 06/30/2018
Fellowship in Hematology & Oncology at Washington University Dept of Ophthalmology-GME

07/01/2013 - 06/30/2015
Residency in Internal Medicine at Washington University in St. Louis

06/01/2012 - 06/30/2013
Internship in Internal Medicine at Washington University in St. Louis

VIEW ALL expand_more


2019 - 2022
Wilmot Fellowship Award
Sponsor: Wilmot Cancer Institute
Location: Rochester, NY

Travel Award, Society of Hematologic Oncology

Harold A. Lyons Award for Excellence in Clinical Medicine

Alpha Omega Alpha
Location: SUNY Downstate College of Medicine

Downstate Alumni Summer Research Fellow

VIEW ALL expand_more

Clinical Trials

Improving Risk Assessment of AML With a Precision Genomic Strategy to Assess Mutation Clearance

Lead Researcher: Eric J Huselton

The investigators will prospectively determine whether the relapse-free and overall survival in patients who have cleared their leukemia-associated mutations treated with standard consolidation chemotherapy is superior to what is expected based on historical controls. The investigators will also prospectively determine the relapse-free and overall survival of patients who have not cleared their mutations. Because the relapse rate of patients with persistent mutations is expected to be high, treatment with either standard of care consolidation therapy alone or alloSCT will be permitted, at the discretion of the treating physician.

View Study Details


Journal Articles

Loh KP, Sanapala C, Jensen-Battaglia M, Rana A, Sohn MB, Watson E, Gilmore N, Klepin HD, Mendler JH, Liesveld J, Huselton E, LoCastro M, Susiarjo M, Netherby-Winslow C, Williams AM, Mustian K, Vertino P, Janelsins MC. "Exercise and epigenetic ages in older adults with myeloid malignancies." European journal of medical research.. 2023 May 30; 28(1):180. Epub 2023 May 30.

LoCastro M, Wang Y, Sanapala C, Jensen-Battaglia M, Wittink M, Norton S, Klepin HD, Richardson DR, Mendler JH, Liesveld J, Huselton E, Loh KP. "Patient preferences, regret, and health-related quality of life among older adults with acute myeloid leukemia: A pilot longitudinal study." Journal of geriatric oncology.. 2023 May 25; 14(5):101529. Epub 2023 May 25.

Rashidi A, Huselton EJ, Stefanski HE, DeFor TE, Shanley R, Choi J, DiPersio JF, Juckett M, Miller JS, Weisdorf DJ, Schroeder MA. "A multicenter phase 2 clinical trial of 10-day decitabine, dose-escalated donor lymphocyte infusion, and ruxolitinib for relapsed acute myeloid leukemia and myelodysplastic syndromes after allogeneic hematopoietic cell transplantation." Transplantation and cellular therapy.. 2023 Feb 17; Epub 2023 Feb 17.